About the Study The study analyzed a dataset generated by linking more than a half million de-identified patients who received the GeneSight test to administrative insurance claim ...

Myriad Genetics (MYGN) announced that the Journal of Clinical Psychopharmacology has published a study showing those with major depressive ...

BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $9 from $11 and keeps an Underperform rating on the shares.Sentiment for Life Sciences and Diagnostic Tools and Contract ...

Myriad Genetics, Inc. SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today ...

In the latest quarter, 10 analysts provided ratings for Myriad Genetics MYGN, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by ...

The junta – which seized power in a 2021 coup sparking a many-sided civil war – said it would cease attacking its myriad ...